Safety and Immunological Effects of Pembrolizumab Plus Ablative Radiotherapy in Patients With Advanced Adrenocortical Carcinoma
Memorial Sloan Kettering Cancer Center
Summary
The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortical Carcinoma.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Be willing and able to provide written informed consent for the trial. * Be ≥ 15 years of age on day of signing informed consent. * Have histologically- or cytologically- confirmed metastatic ACC with symptomatic liver metastases. * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or * Adequate performance status: 1. Patients \< 16 years of age: Lansky ≥ 50% 2. Patients ≥ 16 years of age: Karnofsky ≥ 50% * Have measurable disease based on RECIST v1.1. * Have radiologic documentation of extrahepatic tumor, defined as extrahepatic metastases.…
Interventions
- RadiationAblative Radiotherapy
All participants will first undergo ablative RT
- DrugPembrolizumab
After completion of ablative RT, all subjects may begin pembrolizumab treatment
Locations (7)
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-CommackCommack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York